Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
Amalgamated Bank Lowers Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Amalgamated Bank lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 8.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,003 shares of the company’s stock after selling 1,239 shares during the quarter. Amalgamated Bank’s holdings in Harmony Biosciences were worth $452,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Global Investments purchased a new position in shares of Harmony Biosciences in the 4th quarter valued at approximately $522,000. Los Angeles Capital Management LLC increased its position in Harmony Biosciences by 218.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 24,148 shares of the company’s stock valued at $780,000 after buying an additional 16,555 shares in the last quarter. Jackson Creek Investment Advisors LLC bought a new position in Harmony Biosciences during the 4th quarter valued at approximately $991,000. Paradiem LLC increased its position in Harmony Biosciences by 38.7% during the 4th quarter. Paradiem LLC now owns 107,031 shares of the company’s stock valued at $3,457,000 after buying an additional 29,847 shares in the last quarter. Finally, Truist Financial Corp bought a new position in Harmony Biosciences during the 4th quarter valued at approximately $297,000. Hedge funds and other institutional investors own 86.23% of the company’s stock. Wall Street Analysts Forecast Growth A number of research analysts recently weighed in on HRMY shares. Mizuho reduced their price objective on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $49.00 price objective on shares of Harmony Biosciences in a research report on Friday, April 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 30th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Moderate Buy” and an average target price of $40.63. Read Our Latest Report on HRMY Harmony Biosciences Stock Down 1.0 % Harmony Biosciences stock opened at $29.03 on Monday. The company has a current ratio of 3.11, a quick ratio of 3.07 and a debt-to-equity ratio of 0.34. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $39.26. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of 12.57, a PEG ratio of 0.47 and a beta of 0.75. The stock has a fifty day simple moving average of $30.88 and a two-hundred day simple moving average of $30.86. Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.60 by $0.07. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. The company had revenue of $154.62 million during the quarter, compared to analyst estimates of $154.10 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. Harmony Biosciences’s revenue was up 29.8% compared to the same quarter last year. Equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.53 EPS for the current fiscal year. Insider Buying and Selling In related news, insider Jeffrey Dierks sold 11,979 shares of Harmony Biosciences stock in a transaction on Friday, March 15th. The stock was sold at an average price of $32.00, for a total value of $383,328.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 30.80% of the stock is currently owned by corporate insiders. About Harmony Biosciences (Free Report) Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Read More Five stocks we like better than Harmony Biosciences The How And Why of Investing in Oil Stocks MarketBeat Week in Review – 5/13 – 5/17 Canadian Penny Stocks: Can They Make You Rich? Take-Two Interactive Software Offers 2nd Chance for Investors Transportation Stocks Investing Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report).
